<code id='88789206B8'></code><style id='88789206B8'></style>
    • <acronym id='88789206B8'></acronym>
      <center id='88789206B8'><center id='88789206B8'><tfoot id='88789206B8'></tfoot></center><abbr id='88789206B8'><dir id='88789206B8'><tfoot id='88789206B8'></tfoot><noframes id='88789206B8'>

    • <optgroup id='88789206B8'><strike id='88789206B8'><sup id='88789206B8'></sup></strike><code id='88789206B8'></code></optgroup>
        1. <b id='88789206B8'><label id='88789206B8'><select id='88789206B8'><dt id='88789206B8'><span id='88789206B8'></span></dt></select></label></b><u id='88789206B8'></u>
          <i id='88789206B8'><strike id='88789206B8'><tt id='88789206B8'><pre id='88789206B8'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:29136
          Portrait of Don Davis -- health policy coverage from STAT
          U.S. Representative Don Davis (D-N.C.) Wikimedia Commons

          WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s Medicare drug price negotiation program managed to find themselves a Democratic co-sponsor — even though every single Democrat in Congress in 2022 voted for the legislation.

          They found their perfect candidate in Rep. Don Davis, a Democrat representing a North Carolina district that includes parts of the state’s Research Triangle. He came to Washington in 2023, so didn’t vote on the original law. He received donations in 2023 from the political action committees for Gilead, Astellas, Genentech, Bayer, Pfizer, Novo Nordisk, GSK, Bristol Myers Squibb, BIO, Amgen, Boehringer Ingelheim, Merck, AbbVie, and Eli Lilly.

          advertisement

          “We must support the development of critical, life-sustaining medical treatments and cures,” Davis said in a written statement, and a spokesperson declined to elaborate. He is joined on the bill by Rep. Greg Murphy (R-N.C.) and Brett Guthrie (R-Ky.), the Energy and Commerce health subcommittee chairman.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry
          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

          GwenPetersen,38,anALSpatient,believesthattherecentfailureofAmylyx'sdrugRelyvriocouldstillteachresear

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Pushing for an NIH office for post

          MarkWilson/NewsmakersWhentheWhiteHousereleasedPresidentBiden’s2025budgetrequeststhisweek,fundingforb